7 reports

The company will later select and provide seed funding to one winner.

  • Dermatology
  • Pharmaceutical
  • United States
  • M&A
  • Sandoz Inc.

The prominent features of this report are - ##.

  • Clinical Trial
  • Dermatological Condition
  • Dermatology
  • World
  • Novartis AG

The prominent features of this report are - ##.

  • Dermatological Condition
  • Dermatology
  • Therapy
  • World
  • Novartis AG

The prominent features of this report are - ##.

  • Clinical Trial
  • Dermatological Condition
  • Dermatology
  • World
  • Novartis AG

Overview of the study ## patients were randomized to one of the four nemolizumab dose groups (##. ##, ##. ##, ##. ## mg/ kg every ## week (Q##W) or ##. ## mg/ kg every ## week) or placebo group (Q##W) in the ratio of ##:##:##:##:##.

  • Dermatological Condition
  • Dermatology
  • Pharmaceutical
  • World
  • Novartis AG

The prominent features of this report are - ##.

  • Clinical Trial
  • Dermatology
  • Pharmaceutical
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Clinical Trial
  • Dermatological Condition
  • Dermatology
  • Pharmaceutical
  • World